These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29496225)

  • 1. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review.
    Heidari P; Cross W; Crawford K
    Semin Arthritis Rheum; 2018 Aug; 48(1):12-21. PubMed ID: 29496225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
    Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
    Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter?
    Curkendall S; Patel V; Gleeson M; Campbell RS; Zagari M; Dubois R
    Arthritis Rheum; 2008 Oct; 59(10):1519-26. PubMed ID: 18821651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Out-of-Pocket Costs on Prescription Fills Among New Initiators of Biologic Therapies for Rheumatoid Arthritis.
    Hopson S; Saverno K; Liu LZ; AL-Sabbagh A; Orazem J; Costantino ME; Pasquale MK
    J Manag Care Spec Pharm; 2016 Feb; 22(2):122-30. PubMed ID: 27015251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rheumatologists' insight into medication adherence in patients with rheumatoid arthritis: A qualitative study.
    Heidari P; Cross W; Weller C; Team V; Nazarinia M; Crawford K
    Int J Rheum Dis; 2019 Sep; 22(9):1695-1705. PubMed ID: 31322831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).
    Fautrel B; Balsa A; Van Riel P; Casillas M; Capron JP; Cueille C; de la Torre I
    Curr Med Res Opin; 2017 Jul; 33(7):1231-1246. PubMed ID: 28358217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economics of non-adherence to biologic therapies in rheumatoid arthritis.
    De Vera MA; Mailman J; Galo JS
    Curr Rheumatol Rep; 2014 Nov; 16(11):460. PubMed ID: 25227187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Out-of-pocket medical spending for care in patients with recent onset rheumatoid arthritis].
    Westhoff G; Listing J; Zink A
    Z Rheumatol; 2004 Oct; 63(5):414-24. PubMed ID: 15517302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs.
    Borah BJ; Huang X; Zarotsky V; Globe D
    Curr Med Res Opin; 2009 Jun; 25(6):1365-77. PubMed ID: 19425902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review.
    Pasma A; van't Spijker A; Hazes JM; Busschbach JJ; Luime JJ
    Semin Arthritis Rheum; 2013 Aug; 43(1):18-28. PubMed ID: 23352247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
    Pasma A; Schenk C; Timman R; van 't Spijker A; Appels C; van der Laan WH; van den Bemt B; Goekoop R; Hazes JM; Busschbach JJ
    PLoS One; 2017; 12(2):e0171070. PubMed ID: 28152001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Out-of-Pocket Cost on Medication Initiation, Adherence, and Persistence among Patients with Type 2 Diabetes: The Diabetes Study of Northern California (DISTANCE).
    Karter AJ; Parker MM; Solomon MD; Lyles CR; Adams AS; Moffet HH; Reed ME
    Health Serv Res; 2018 Apr; 53(2):1227-1247. PubMed ID: 28474736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany: I. Selected DMARDs and patient-related costs.
    Schädlich PK; Zeidler H; Zink A; Gromnica-Ihle E; Schneider M; Straub C; Brecht JG; Huppertz E
    Pharmacoeconomics; 2005; 23(4):377-93. PubMed ID: 15853437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?
    Wong PK
    Rheumatol Int; 2016 Nov; 36(11):1535-1542. PubMed ID: 27665289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.
    Curtis JR; Bykerk VP; Aassi M; Schiff M
    J Rheumatol; 2016 Nov; 43(11):1997-2009. PubMed ID: 27803341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review.
    Blum MA; Koo D; Doshi JA
    Clin Ther; 2011 Jul; 33(7):901-13. PubMed ID: 21715007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA.
    Tanaka E; Hoshi D; Igarashi A; Inoue E; Shidara K; Sugimoto N; Sato E; Seto Y; Nakajima A; Momohara S; Taniguchi A; Tsutani K; Yamanaka H
    Mod Rheumatol; 2013 Jul; 23(4):742-51. PubMed ID: 22878927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target?
    Modena V; Bianchi G; Roccatello D
    Autoimmun Rev; 2013 Jun; 12(8):835-8. PubMed ID: 23219766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.